Effect of ketoconazole on the pharmacokinetic profile of ambrisentan

Journal of Clinical Pharmacology

Volumn 49, Issue 6, 2009, Pages 719-724

  Richards, Duncan B ^a   Walker, Gennyne A ^b   Mandagere, Arun ^b   Magee, Mindy H ^c   Henderson, Linda S ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GILEAD SCIENCES   (United States)

^c Department of Quantitative Science ^*

^d GLAXOSMITHKLINE   (United States)

Author keywords

Ambrisentan; CYP3A4; Ketoconazole; Pharmacokinetics

Indexed keywords

4 HYDROXYMETHYLAMBRISENTAN; AMBRISENTAN; CYTOCHROME P450 3A4; DRUG METABOLITE; KETOCONAZOLE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INTERACTION; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; SIDE EFFECT; SINGLE DRUG DOSE; TENSION HEADACHE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; VITAL SIGN;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; PHENYLPROPIONATES; PYRIDAZINES;

EID: 67149130234     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009335870     Document Type: Article

References (8)

1. Galiè N, Olschewski H, Oudiz RJ, et al; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010-3019.
2. Bjomsson TD, Callaghan JT, Einolf HJ, et al; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/ Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER). The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003;31:815-832.
3. Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol. 2004;44:1054-1062.
4. Dorani H, Schiitzer KM, Sarich TC, et al. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximela-gatran co-administered with different classes of antibiotics in healthy volunteers. Eur J Clin Pharmacol. 2007;63:571-581.
5. Chung E, Nafziger AN, Kazierad DJ, Bertino JS Jr. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther. 2006;79:350-361.
6. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of keto-conazole. Clin Pharmacol Ther. 1999;66:461-471.
7. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketocona-zole or itraconazole. Clin Pharmacol Ther. 1994;55:481-485.
8. van Giersbergen PL, Halabi A, Dingemanse J. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol. 2002;53:589-595.